+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 365Days - 25Years
All Genders
ID03959085

Randomized Trial of Inotuzumab Ozogamicin Added to Post-Induction Chemotherapy for High-Risk B-Cell Acute Lymphoblastic Leukemia and Related Leukemias

Led by Children's Oncology Group · Updated on 2026-08-25

5951

Participants Needed

231

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether adding inotuzumab ozogamicin to post-induction chemotherapy and immunotherapy improves outcomes for children and young adults with High-Risk B-cell Acute Lymphoblastic Leukemia B-ALL. This phase III trial also studies patients with mixed phenotype acute leukemia MPAL and B-lymphoblastic lymphoma B-LLy treated with standard acute lymphoblastic leukemia therapy. The study aims to understand if this addition maintains or improves five-year event-free survival and assesses side effects, quality of life, treatment adherence, immune impact, and social factors affecting outcomes. Participants first receive induction therapy with a combination of chemotherapy drugs including vincristine, daunorubicin, methotrexate, and steroids, among others. After induction, patients with high-risk B-ALL and CD22 positive status are randomized into two groups one receiving standard chemo-immunotherapy including blinatumomab Arm D, and the other receiving modified chemo-immunotherapy with inotuzumab ozogamicin replacing parts of consolidation and delayed intensification Arm E. Patients with MPAL and B-LLy receive tailored chemotherapy regimens without inotuzumab. Treatment phases include consolidation, blinatumomab blocks, interim maintenance, delayed intensification, and maintenance therapy over up to two years. Throughout the study, participants undergo blood sample collection, bone marrow aspiration and biopsy, and imaging studies such as CT, MRI, PET, and bone scans as appropriate. Researchers monitor treatment effects, adverse events, and quality of life using patient-reported outcomes. After completing treatment, participants are followed for up to five years with regular visits to assess disease status, survival, and long-term effects.

CONDITIONS

Brief Title

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here